Zomedica, Celsee Inc. partner to deliver cancer liquid biopsy platformDecember 21, 2017Zomedica Pharmaceuticals Corp. has entered into a license and supply agreement with Celsee Inc., an innovator of progressive rare cell capture, characterization, and retrieval products in the emerging field of liquid biopsy. Under the terms of the agreement, Zomedica will have animal health exclusive global rights to develop and market Celsee's liquid biopsy platform for use by veterinarians as a cancer diagnostic. A liquid biopsy is a blood test with the potential to detect the presence of circulating tumor cells in the blood. Circulating tumor cells (CTC) are shed from a primary tumor into neighboring blood vessels and are transported throughout the body's circulatory system. The detection of CTCs in the blood could indicate a cancer diagnosis without the need for an invasive tissue biopsy, according to Zomedica. "Liquid biopsy is cutting-edge technology in human medicine right now and we're excited about the opportunity to develop and market this platform for use in veterinary medicine," stated Gerald Solensky, Jr., CEO at Zomedica. "We selected the Celsee platform because of the ease of use, workflow simplicity, and flexibility to use our novel canine biomarkers. If we successfully develop Celsee's technology, we believe we will be able to …
SPONSORED CONTENTA new way to offer multi-organ supportNEW Hill's Prescription Diet Multi-Organ offers therapeutic nutrition for pets that may have conflicting nutritional needs. + Learn More
Giving the topic of sound veterinary nutrition the respect it deservesDecember 20, 2017Do enough professionals among the veterinary profession treat companion animal nutrition with the significance it deserves? What's driving the US pet obesity epidemic? Are practitioners doing enough to address it? Veterinary Practice News asked Martha G. Cline, DVM, DACVN, president, American Academy of Veterinary Nutrition, and a clinical veterinary nutritionist at AAHA-accredited Red Bank Veterinary Hospital in Tinton Falls, N.J., these questions and more about the topic of diet and nutrition. Here's what she had to share. Why did you decide to specialize in veterinary nutrition? During the summer between my first and second year of veterinary school, I worked with the nutrition department at the University of Tennessee College of Veterinary Medicine (UTCVM) through a summer research program. The focus of this research was canine obesity. This experience was the foundation of my interest, which solidified during my clinical year when I spent additional time rotating through the nutrition services at UTCVM, Oradell Animal Hospital in Paramus, N.J., and Angell Animal Medical Center in Boston. I had excellent mentorship at all of these facilities that helped guide me on my way (shout out to Drs. Angela Witzel, Joe Bartges, Claudia Kirk, Laura …
USDA grants Zoetis' Vanguard Rapid Resp one-year DOIDecember 19, 2017The USDA has granted Zoetis' Vanguard Rapid Resp intranasal vaccine line one-year duration of immunity (DOI) claims for Bordetella bronchiseptica, canine adenovirus type 2 (CAV-2), and canine parainfluenza virus (CPiV). Vanguard Rapid Resp is the first and only intranasal vaccine line in the US that has been demonstrated to provide one year of protection against three important canine infectious respiratory diseases (CIRD), according to the company. "The demonstration of a one-year duration of immunity for all three antigens in Vanguard Rapid Resp represents an important step in the protection of dogs from CIRD. This new DOI confirms the efficacy of a single product that provides both rapid and durable protection against these important antigens in the CIRD complex," said Stephan Carey, DVM, Ph.D., DACVIM, assistant professor of Small Animal Clinical Sciences at Michigan State University College of Veterinary Medicine, consultant for Zoetis. "This extended DOI is essential in reducing morbidity and mortality from infectious respiratory disease among dogs in social or commingled environments such as boarding facilities and shelters." Vanguard Rapid Resp is available in three antigenic combinations (Bb + CPiV + CAV-2; Bb + CPiV; Bb only), and all of these choices can be administered with a syringe …
The beat goes onDecember 15, 2017Dogs love their human families with their whole hearts, and the humans who love them back want to keep their beloved companions’ hearts healthy.
Dog and cat behavior myths debunkedDecember 15, 2017Veterinary behavior is a relatively new specialty in our profession. Unfortunately, as such, plenty of old wives tales persist. As veterinarians and veterinary nurses, we critically evaluate and use evidenced-based medicine for our patients on a daily basis, and this should apply to behavior and training, as well. Here are some of the most common misconceptions about our patient's behaviors that still are being propagated, despite scientific evidence to the contrary. Myth No. 1: Human dominance maintains proper structure and obedience Common things we hear: "Don't let your dog sleep on the bed or couch because you don't want them to think they're dominant." "You need to alpha roll your dog to show him who's boss." "Once I put him in his place, he behaved perfectly." "You need to always be the alpha." No species in the animal kingdom creates dominance hierarchies with another species. However, dogs do create dominance hierarchies among themselves. This fluid relationship is maintained primarily by the deferential dog and not the most assertive. Take, for example, two household dogs each given a rawhide. The two go to their respective corners. One dog finishes first, then approaches the other and takes the second chew for himself. …
What Veterinary Practice News readers loved in 2017December 15, 2017Another new year is upon us, but before we embrace 2018 and all it might have to offer veterinary professionals and the industry, let's recap Veterinary Practice News' 10 most-read features of 2017. 1. Canine influenza virus 2017: Beyond two show dogs 2. 10 secrets to keep your veterinary nurses happy 3. University of Minnesota develops cancer drug that helps dogs with hemangiosarcoma 4. Study: Cats eating dry food have increased risk for developing Type 2 diabetes 5. Zoetis earns license for Cytopoint skin therapy 6. Raising greyhound health awareness 7. American Association of Feline Practitioners revises declawing position 8. The 7 top challenges facing veterinary medicine in 2017 9. Petco officially enters the veterinary hospital ring with Thrive 10. The strangest things vet techs have heard clients say
Let there be lightDecember 13, 2017Veterinary professionals say laser therapy can provide clinically significant benefits and expand options for delivering compassionate care with fewer drugs and less surgery.
Zomedica announces therapeutic development milestonesDecember 13, 2017Zomedica Pharmaceuticals Corp. veterinary pharmaceutical and diagnostic company announced a development update on the company's four therapeutic candidates for use in companion animals, namely dogs and cats. ZM-012 and ZM-007: Metronidazole for acute diarrhea in dogs Development milestones for ZM-012 and ZM-007, complementary oral formulations of metronidazole targeting the treatment of acute diarrhea in dogs include: Finalized novel tablet formulation for ZM-012 to replace the large, bitter tasting human-approved generic tablet commonly prescribed by veterinarians for their canine patients. The beef-flavored oral tablets are intended for dogs greater than 9 pounds or 4 kilograms. Finalized the oral suspension formulation for ZM-007, which is intended for small breeds and puppies under 9 pounds or 4 kilograms. Completed pilot testing for both formulations at Michigan State University College of Veterinary Medicine to measure metronidazole's effectiveness to treat acute diarrhea in dogs. Scheduled December 2017 pre-submission meeting with the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) to present the regulatory strategy and development plan for ZM-012. A safety study will commence for ZM-012 in the first half of 2018 for completion in the second half of 2018. The company also expects to hold a pre-submission …
Drug-resistant heartworm strain found in Louisiana LabradorDecember 12, 2017A drug-resistant strain of heartworm was discovered in a dog in Metairie, La., according to local veterinarian, Cynthia Benbow, DVM, CVA. Maddie, a yellow lab from Metairie, was a patient of Dr. Benbow. According to the news release issued by Benbow's office, Maddie contracted heartworm while on a monthly preventive. The heartworms had resurfaced in Benbow's long-time patient after a bout three years prior even though Maddie's owner had, as Benbow described, "religiously" stuck with the prescribed prevention regimen. Testing revealed the dog was infected with a drug-resistant strain of heartworm. A sample of Maddie's blood was sent to Ray Kaplan, DVM, at the Department of Infectious Diseases at University of Georgia (UGA) College of Veterinary Medicine, according to Benbow. Dr. Kaplan's lab confirmed that the heartworms were indeed drug-resistant, and established the strain for research purposes, naming it Metairie-2014. Louisiana hosts "by far the most cases" of suspected drug-resistant heartworm strains, according to Cassan Pulaski, a doctoral candidate at Louisiana State University (LSU). Southern states show higher incidences of likely drug-resistant strains, particularly those surrounding the Mississippi River Delta, he said. It's unknown how many drug-resistant heartworm strains exist because local veterinarians do not have the research tools to verify resistant strains, according to …
Zoetis launches Vanguard CIV H3N2/H3N8 vaccine for canine influenzaDecember 12, 2017Zoetis' Vanguard CIV H3N2/H3N8 is a new bivalent vaccine helps protect dogs against CIV H3N2 and CIV H3N8, which have caused serious disease outbreaks in 38 states across the US.1 In an efficacy study, dogs that received the Vanguard CIV H3N2/H3N8 vaccine were protected from disease after CIV H3N2 challenge.2,3,4 Vaccination also appeared to help decrease the number of days after challenge that dogs shed CIV H3N2 virus—from an average of 4.9 days in the placebo-vaccinated controls to an average of 1.3 days in Vanguard CIV H3N2/H3N8 vaccinates.2,5,6 During a safety study that involved 364 dogs, including 164 client-owned dogs and 200 dogs from commercial breeding facilities, 725 doses of vaccine were administered and no significant adverse events were observed.7 Dogs that frequently are in the company of others could benefit from the protection Vanguard CIV H3N2/H3N8 offers, said Stephan Carey, DVM, Ph.D., DACVIM, assistant professor, Small Animal Clinical Sciences at Michigan State University College of Veterinary Medicine, and past president of The Veterinary Comparative Respiratory Society, and Zoetis consultant. "Dogs that attend day care, visit the dog park, or stay at boarding facilities are all at risk for contracting either strain of CIV," he said. …
